Core Viewpoint - Xinnoway is a leading company in the functional food industry in China, with strong technical capabilities and market competitiveness in research, production, and sales of functional foods [1] Group 1: Business Performance - In Q3 2025, Xinnoway reported revenue of 1.593 billion yuan, ranking 11th among 47 companies in the industry, with the industry leader, Puluo Pharmaceutical, generating 7.764 billion yuan [2] - The net profit for the same period was -310 million yuan, placing the company at the bottom of the industry rankings, while the top performer, Zhejiang Pharmaceutical, achieved a net profit of 867 million yuan [2] Group 2: Financial Ratios - As of Q3 2025, Xinnoway's debt-to-asset ratio was 32.94%, higher than the previous year's 16.97% and above the industry average of 27.75% [3] - The gross profit margin for Q3 2025 was 39.68%, down from 42.99% year-on-year but still above the industry average of 35.38% [3] Group 3: Shareholder Information - As of September 30, 2025, the number of A-share shareholders increased by 3.45% to 16,400, while the average number of circulating A-shares held per account decreased by 3.34% to 76,000 [5] - The top ten circulating shareholders included Hong Kong Central Clearing Limited and several mutual funds, with notable changes in their holdings [5] Group 4: Future Outlook - According to Shenwan Hongyuan, Xinnoway's revenue is expected to grow, with a projected income of 2.19 billion yuan in 2025, 2.49 billion yuan in 2026, and 2.8 billion yuan in 2027, alongside a gradual improvement in net profit [6] - Dongwu Securities highlighted a slight revenue increase in H1 2025, with significant profit decline attributed to rising expense ratios, while emphasizing the potential of new drug developments [6]

本报记者 毛艺融 瑞银证券全球投资银行部联席主管谌戈对《证券日报》记者表示："在香港市场上市将助力A股公司全 球业务发展，为公司的国际化战略提供支持，通过提升全球范围内的市场认可度，有效增强公司在国际 战略合作或收购中的竞争力和话语权。此外，港股的股权激励计划更加市场化，有助于公司吸引更多国 际人才。" 多方面因素助推 A股公司密集赴港上市，是政策支持、市场流动性改善等多重因素作用的结果。 政策方面，港交所持续优化上市规则，吸引优质A股公司赴港上市。继为百亿港元市值以上的A股公司 开设快速审核通道后，今年8月份，港交所进一步放宽了对"A+H"股公司的公众持股限制，满足"30亿港 元预期市值"或"10%公众持股量"其中一项即可，由原规则的双重要求改为二选一。 A股公司赴港上市步伐加快。 Wind数据显示，截至10月13日，年内已有11家A股公司完成"A+H"上市，数量上仅次于2015年的15家、 1997年的13家。另外，仅10月份以来，已有三一重工股份有限公司、上海剑桥科技股份有限公司、深圳 市广和通无线股份有限公司、赛力斯集团股份有限公司等4家A股公司的H股上市聆讯通过，即将加 入"A+H"阵营。 沙利文大 ...

Core Viewpoint - The company is preparing for its H-share listing by revising its articles of association and governance structures to comply with regulatory requirements in both domestic and international markets [1][2]. Group 1: Articles of Association - The company held its 26th meeting of the sixth board of directors on September 30, 2025, to review multiple proposals related to the H-share issuance and listing [1]. - The revised articles of association cover various aspects including establishment basis, listing information, total shares, capital increase/decrease methods, share acquisition, transfer, shareholder rights and obligations, and the powers of the shareholders' and board meetings [1]. - Specific details such as the listing time and number of shares to be issued are included in the revised articles, which will take effect upon the H-share listing on the Hong Kong Stock Exchange [1]. Group 2: Governance Structure - The company is also revising and formulating several governance documents, including 17 key rules such as the "Rules of Procedure for Shareholders' Meetings" and "Rules of Procedure for Board Meetings" [2][3]. - The first four governance documents require approval from the shareholders' meeting, indicating a structured approach to governance reform [2]. - These adjustments are crucial for the company to align with the regulatory requirements of the capital markets and to enhance its governance structure [2].

Group 1 - The core point of the news is that XinNuoWei's stock price has been declining, with a total drop of 9.61% over the last three days, closing at 46.47 CNY per share on September 29, with a market capitalization of 65.271 billion CNY [1] - XinNuoWei's main business involves the research, production, and sales of functional foods, which account for 88.93% of its revenue, while biopharmaceuticals contribute 8.91% and other sources 2.16% [1] - The company is located in Shijiazhuang, Hebei Province, and was established on April 5, 2006, with its listing date on March 22, 2019 [1] Group 2 - According to data from the top ten holdings of funds, one fund under JiaoYin ShiLuoDe has a significant position in XinNuoWei, specifically the JiaoYin Medical Innovation Stock A fund, which reduced its holdings by 651,000 shares in the second quarter [2] - The JiaoYin Medical Innovation Stock A fund currently holds 2.3373 million shares of XinNuoWei, representing 4.66% of the fund's net value, making it the fifth-largest holding [2] - The fund has experienced a floating loss of approximately 3.0853 million CNY today and a total floating loss of 11.5464 million CNY during the three-day decline [2]

Core Viewpoint - The company reported a revenue of 1.05 billion RMB for the six months ending June 30, 2025, reflecting a year-on-year growth of 7.99% [1] - The net loss attributable to shareholders was 2.746 million RMB, a significant decline from a net profit of 137 million RMB in the same period last year [1] - The basic loss per share was 0.0020 RMB [1] Financial Performance - Revenue for the period reached 1.05 billion RMB, marking a 7.99% increase compared to the previous year [1] - The company experienced a net loss of 2.746 million RMB, contrasting with a net profit of 137 million RMB from the prior year [1] - Basic loss per share was reported at 0.0020 RMB [1]

Group 1 - The company reported a revenue of 1.05 billion RMB for the six months ending June 30, 2025, representing a year-on-year growth of 7.99% [1] - The net loss attributable to shareholders was 2.746 million RMB, compared to a net profit of 137 million RMB in the same period last year [1] - The basic loss per share was 0.0020 RMB [1]

天眼查商业履历信息显示，石药创新制药股份有限公司，成立于2006年，位于石家庄市，是一家以从事 医药制造业为主的企业。企业注册资本140459.2944万人民币，实缴资本15000万人民币。公司法定代表 人为姚兵。 通过天眼查大数据分析，石药创新制药股份有限公司共对外投资了7家企业，参与招投标项目32次，专 利信息59条，此外企业还拥有行政许可58个。 来源：金融界 金融界消息 截至2025年8月15日收盘，新诺威（300765）报收于53.0元，上涨0.99%，换手率0.59%，成 交量7.41万手，成交金额3.88亿元。 资金流向方面，今日主力资金净流出1387.75万元，占比成交额3.58%。其中，超大单净流入156.16万 元、占成交额0.4%，大单净流出1543.90万元、占成交额3.98%，中单净流出流出1385.19万元、占成交 额3.57%，小单净流入2772.94万元、占成交额7.15%。 新诺威最新一期业绩显示，截至2025中报，公司营业总收入10.50亿元、同比增长7.99%，归属净利润 274.61万元，同比减少102.00%，扣非净利润4114.41万元，同比减少130.59%，流动 ...

来源：金融界 金融界消息 截至2025年8月5日收盘，新诺威（300765）报收于51.56元，上涨0.16%，换手率0.8%，成 交量9.94万手，成交金额5.10亿元。 天眼查商业履历信息显示，石药创新制药股份有限公司，成立于2006年，位于石家庄市，是一家以从事 医药制造业为主的企业。企业注册资本140459.2944万人民币，实缴资本15000万人民币。公司法定代表 人为姚兵。 通过天眼查大数据分析，石药创新制药股份有限公司共对外投资了7家企业，参与招投标项目32次，专 利信息59条，此外企业还拥有行政许可58个。 资金流向方面，今日主力资金净流出1734.51万元，占比成交额3.4%。其中，超大单净流出1209.74万 元、占成交额2.37%，大单净流出524.77万元、占成交额1.03%，中单净流出流入613.85万元、占成交额 1.2%，小单净流入1120.66万元、占成交额2.2%。 新诺威最新一期业绩显示，截至2025一季报，公司营业总收入4.72亿元、同比减少9.94%，归属净利润 2690.16万元，同比减少134.03%，扣非净利润3063.61万元，同比减少139.19%，流动比率1 ...

金融界消息 截至2025年7月29日收盘，新诺威（300765）报收于56.1元，上涨7.1%，换手率1.03%，成 交量12.85万手，成交金额7.18亿元。 资金流向方面，今日主力资金净流入9170.78万元，占比成交额12.78%。其中，超大单净流入6589.69万 元、占成交额9.18%，大单净流入2581.10万元、占成交额3.6%，中单净流出流出3758.54万元、占成交 额5.24%，小单净流出5412.25万元、占成交额7.54%。 新诺威最新一期业绩显示，截至2025一季报，公司营业总收入4.72亿元、同比减少9.94%，归属净利润 2690.16万元，同比减少134.03%，扣非净利润3063.61万元，同比减少139.19%，流动比率1.774、速动比 率1.515、资产负债率28.47%。 通过天眼查大数据分析，石药创新制药股份有限公司共对外投资了7家企业，参与招投标项目32次，专 利信息59条，此外企业还拥有行政许可58个。 天眼查商业履历信息显示，石药创新制药股份有限公司，成立于2006年，位于石家庄市，是一家以从事 医药制造业为主的企业。企业注册资本140459.2944万人民币 ...

Core Viewpoint - New Nuo Wei (300765.SZ) announced the termination of its application for the acquisition of Shiyao Chuangxin Pharmaceutical Co., Ltd. and the associated fundraising, ending a 15-month effort for a significant restructuring deal worth 7.6 billion yuan [2][3]. Group 1: Termination of Acquisition - The termination was due to changes in the pharmaceutical industry and capital market environment since the initial planning of the restructuring, leading to a decision made in the interest of long-term shareholder benefits [2][3]. - The market reacted rationally to the termination, influenced by factors such as stock price fluctuations, increasing performance burdens, and declining acquisition targets [2][3]. Group 2: Financial Performance and Challenges - New Nuo Wei's revenue and profit have been declining, with a 21.98% year-on-year decrease in revenue to 1.981 billion yuan and an 87.63% drop in net profit to 54 million yuan in 2024 [8]. - The company's core revenue from functional foods and raw materials fell by 24.90% to 1.84 billion yuan, while the biopharmaceutical sector contributed only 87.8 million yuan, despite a 153.0% increase [10]. Group 3: Acquisition Details and Valuation - The acquisition target, Shiyao Baike, has a core product, Jinyouli, which is facing growth challenges, with a significant reliance on a single product and limited growth potential [4][7]. - The valuation for Shiyao Baike was set at 7.622 billion yuan, representing a 78.25% premium over its book value of 4.276 billion yuan, raising concerns about the high price for low-growth assets [6][7]. Group 4: R&D and Future Prospects - New Nuo Wei's R&D expenses increased by 25.44% to 842 million yuan in 2024, primarily due to the inclusion of Shiji Biological's R&D costs, indicating a significant financial burden [10][11]. - The company is under pressure from negative cash flows, with net cash flow from operating activities at -1.235 billion yuan in 2024 and -87 million yuan in the first quarter of 2025 [12][13].